From the publishers of JADPRO

Metastatic HER2-Positive Breast Cancer Resource Center


Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort

Last Updated: Wednesday, March 8, 2023

Among patients with HER2-positive metastatic breast cancer who experienced isolated CNS progression after receiving first-line trastuzumab and pertuzumab (T/P), continuing T/P after local treatment did not negatively impact PFS and OS, according to data from a retrospective review of real-life data. No difference in PFS was seen for patients who continued T/P or switched to another systemic treatment, and T/P continuation was associated with longer OS (HR 0.28; 95% CI: 0.14ā€“0.54; pā€‰<ā€‰0.001).

Breast Cancer
News & Literature Highlights

Nature Reviews Drug Discovery

Targeting HER2-positive breast cancer: advances and future directions

ESMO Congress 2022 Abstract

Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

ESMO Congress 2022 Abstract

Clinical safety and pharmacokinetics (PK) data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer

ESMO Congress 2022 Abstract

Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan

Cancer Network

Early efficacy observed with trastuzumab deruxtecan ± pertuzumab for HER2+ metastatic breast cancer

Oncology Nursing News

DESTINY-Breast02 confirms benefit of trastuzumab deruxtecan in previously treated patients with HER2+ metastatic breast cancer

Targeted Oncology

Safety of tucatinib triplet for HER2+ breast cancer sealed in real-world analysis

The ASCO Post

T-DXd confirmed as preferred second-line therapy for metastatic HER2-positive breast cancer

Clinical Breast Cancer

A phase II single-arm study of palbociclib in patients with HER2-positive breast cancer with brain metastases and analysis of ctDNA in patients with active brain metastases

Frontiers in Oncology

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review